» Articles » PMID: 8719032

Somatostatin

Overview
Publisher Springer
Date 1995 Dec 1
PMID 8719032
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

1. Somatostatin (SRIF) exerts diverse physiological actions in the body including regulation of hormone and neurotransmitter release and neuronal firing activity. Analogs of SRIF are used clinically to treat tumors and cancers and to block the hypersecretion of growth hormone in acromegaly. 2. The recent cloning of five SRIF receptor subtypes has allowed for the identification of the molecular basis of the cellular actions of SRIF. The ligand binding domains and regions involved in coupling to G proteins and cellular effector systems are being identified and the processes by which SRIF inhibits cell growth and proliferation are being established. Furthermore, subtype selective agonists have been generated which are being used to investigate the specific biological roles of each SRIF receptor subtypes. 3. Such information will be useful in developing a new generation of SRIF drugs that could be employed to treat metabolic diseases, disorders of the gut, cancer and abnormalities in the central nervous system such as epilepsy and Alzheimer's disease.

Citing Articles

Opioids potentiate electrical transmission at mixed synapses on the Mauthner cell.

Cachope R, Pereda A J Neurophysiol. 2015; 114(1):689-97.

PMID: 26019311 PMC: 4512248. DOI: 10.1152/jn.00165.2015.


The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).

van Dijk P, Landman G, van Essen L, Struck J, Groenier K, Bilo H BMC Endocr Disord. 2015; 15:19.

PMID: 25880900 PMC: 4404603. DOI: 10.1186/s12902-015-0009-2.


Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain.

Shi T, Xiang Q, Zhang M, Barde S, Kai-Larsen Y, Fried K Mol Pain. 2014; 10:12.

PMID: 24521084 PMC: 3943448. DOI: 10.1186/1744-8069-10-12.


The somatostatinergic system in the mammalian cochlea.

Radojevic V, Hanusek C, Setz C, Brand Y, Kapfhammer J, Bodmer D BMC Neurosci. 2011; 12:89.

PMID: 21896184 PMC: 3176192. DOI: 10.1186/1471-2202-12-89.


Evolutionary history of the somatostatin and somatostatin receptors.

Moaeen-Ud-Din M, Yang L J Genet. 2009; 88(1):41-53.

PMID: 19417543 DOI: 10.1007/s12041-009-0006-1.


References
1.
Feniuk W, Dimech J, Humphrey P . Characterization of somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium. Br J Pharmacol. 1993; 110(3):1156-64. PMC: 2175805. DOI: 10.1111/j.1476-5381.1993.tb13935.x. View

2.
FITZPATRICK V, Vandlen R . 6agonist selectivity determinants in somatostatin receptor subtypes I and II. J Biol Chem. 1994; 269(40):24621-6. View

3.
Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R . Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A. 1993; 90(9):4196-200. PMC: 46473. DOI: 10.1073/pnas.90.9.4196. View

4.
Wulfsen I, Meyerhof W, Fehr S, Richter D . Expression patterns of rat somatostatin receptor genes in pre- and postnatal brain and pituitary. J Neurochem. 1993; 61(4):1549-52. DOI: 10.1111/j.1471-4159.1993.tb13654.x. View

5.
Mandarino L, Stenner D, Blanchard W, Nissen S, Gerich J, Ling N . Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature. 1981; 291(5810):76-7. DOI: 10.1038/291076a0. View